Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria.

Abstract

BACKGROUND:

Omalizumab is the best treatment for patients with chronic spontaneous urticaria (CSU). Machine learning (ML) approaches can be used to predict response to therapy and the effectiveness of a treatment. No studies are available on the use of ML techniques to predict the response to Omalizumab in CSU.

METHODS:

Data from 132 CSU outpatients were analyzed. Urticaria Activity Score over 7 days (UAS7) and treatment efficacy were assessed. Clinical and demographic characteristics were used for training and validating ML models to predict the response to treatment. Two methodologies were used to label the data based on the response to treatment (UAS7 ≥ 6): (A) at 1, 3 and 5 months; (B) classifying the patients as early responders (ER), late responders (LR) or non-responders (NR) (ER: UAS 7 ≥ 6 at first month, LR: UAS 7 ≥ 6 at third month, NR: if none of the previous conditions occurred).

RESULTS:

ER were predominantly characterized by hypertension, while LR mainly suffered from asthma and hypothyroidism. A slight positive correlation (R2 = 0.21) was found between total IgE levels and UAS7 at 1 month. Variable Importance Analysis (VIA) reported D-dimer and C-reactive proteins as the key blood tests for the performance of learning techniques. Using methodology (A), SVM (specificity of 0.81) and k-NN (sensitivity of 0.8) are the best models to predict LR at the third month.

CONCLUSION:

k-NN plus the SVM model could be used to identify the response to treatment. D-dimer and C-reactive proteins have greater predictive power in training ML models.

• Authors: Davide Stefano Sardina, Giuseppe Valenti, Francesco Papia, Carina Gabriela Uasuf
• Journal: Diagnostics (Basel, Switzerland) (Diagnostics (Basel)) Vol. 11 Issue 11 (Nov 20 2021) ISSN: 2075-4418 [Print] Switzerland
• PMID: 34829497 (Publication Type: Journal Article)